Proton pump inhibitors and risk of colorectal cancer

GutAbrahami D, McDonald EG, Schnitzer ME, et al. | July 02, 2021

Advertisement

This study attempted to ascertain if proton pump inhibitors (PPIs) are correlated with an increased risk of colorectal cancer, compared with histamine-2 receptor antagonists (H2RAs). Researchers used United Kingdom Clinical Practice Research Datalink to distinguish initiators of PPIs and H2RA from 1990 to 2018, with follow-up until 2019. They used Cox proportional hazards models to calculate marginal HRs and 95% CIs of colorectal cancer. The study enrolled 1,293,749 and 292 387 initiators of PPIs and H2RAs, respectively, followed for a median duration of 4.9 years. The findings suggest that prolonged use may be correlated with a modest increased risk of this malignancy, while any use of PPIs was not correlated with an increased risk of colorectal cancer compared with H2RAs.

Read the full article on Gut

Advertisement